BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 02, 2012
 |  BioCentury  |  Emerging Company Profile

Arsanis: Antibodies for infection

Arsanis developing antibodies for bacterial diseases, nosocomial infections

By targeting conserved sequences of bacterial proteins as well as bacterial toxins, Arsanis Inc. expects its antibody cocktails to improve outcomes in infections that are resistant to conventional antibiotics.

Arsanis was created when its three founders, one from Intercell AG, and two from Adimab LLC, realized they had complementary goals.

Managing Director and co-founder Eszter Nagy was SVP and head of global research at Intercell, where she oversaw the antibody platform acquired from Cytos Biotechnology AG in 2010. Despite the acquisition, she said, Intercell remained "clinically focused" on vaccines, and it was "difficult" to advance antibody programs.

Meanwhile, Adimab CEO Tillman Gerngross and COO Errik Anderson were seeking ways to use their yeast-based antibody discovery platform for new diseases while avoiding what Gerngross calls "the temptation for many platform companies to become a drug company. We decided that's not what we're going to do."

Gerngross and Anderson remain at Adimab but also became chairman and a director at...

Read the full 786 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >